Impact of hyperglycaemia and genetic polymorphism in diabetic patients affected by Covid-19

Abstract

The world is facing one of the worst pandemics today, where around 4.7 million people lost their lives due to COVID-19. However, people with chronic diseases are more susceptible to worsening their clinical condition when affected by the new coronavirus. Patients with Diabetes mellitus (DM) promote a chronic inflammatory state and when affected by COVID-19, they are more prone to changes in the innate immune system, which can even trigger a storm of cytokines that is harmful to the host. Our objective was to address the impact of genetic polymorphism involving ACE 2 and clinical severity in people with hyperglycemia affected by COVID-19. This is a literature review with a qualitative approach, carried out on the PUBMED portal. The following search string was used: Polymorphism genetic, Diabetes, COVID-19, Hyperglycemia and Critical Care. Regarding polymorphism, it was observed that some variations may play a role in influencing the entry of the virus into the host body and others may be a useful tool to predict disease development and treatment against COVID-19.